BACKGROUND: B-type natriuretic peptide (BNP) is secreted from cardiomyocytes and may reflect haemodynamic abnormalities predisposing to atrial fibrillation (AF). We aimed to investigate whether N-terminal pro BNP (NT-proBNP) is associated with newly detected AF in subjects obtained from the general population. METHODS: From the PREVEND programme (n=8592), we selected all subjects with an available baseline and four-year electrocardiogram and NTproBNP levels at baseline. We excluded subjects with AF at baseline and subjects with a serum creatinine >2.0 mg/dl. RESULTS: In total, 6494 subjects were eligible for the prospective analysis (aged 49+/-12 years, 49.7% men). At four years, AF was detected in 41 (0.6%) subjects. Median NT-proBNP levels at baseline in subjects with newly detected AF after four years was 62.2 (22.6 to 208.5) pg/ml as compared with 35.7 (15.9 to 68.7) pg/ml in those with sinus rhythm (p=0.001). Each 1 standard deviation increment in natural log transformed NT-proBNP was associated with a 54% (5% to 126%, p=0.028) increase in risk for AF after adjustment for other risk factors predisposing to AF. NT-proBNP levels above the sex-specific 80th percentile (97 pg/ml in women and 60 pg/ml in men) were associated with a multivariate odds ratio of 2.65 (1.22 to 5.76, p=0.01) for the occurrence of AF. CONCLUSION: Plasma levels of NT-proBNP predict newly detected AF in subjects obtained from the general population independent of cardiovascular risk factors predisposing to AF. (Neth Heart J 2008;16:73-8.).
BACKGROUND:B-type natriuretic peptide (BNP) is secreted from cardiomyocytes and may reflect haemodynamic abnormalities predisposing to atrial fibrillation (AF). We aimed to investigate whether N-terminal pro BNP (NT-proBNP) is associated with newly detected AF in subjects obtained from the general population. METHODS: From the PREVEND programme (n=8592), we selected all subjects with an available baseline and four-year electrocardiogram and NTproBNP levels at baseline. We excluded subjects with AF at baseline and subjects with a serum creatinine >2.0 mg/dl. RESULTS: In total, 6494 subjects were eligible for the prospective analysis (aged 49+/-12 years, 49.7% men). At four years, AF was detected in 41 (0.6%) subjects. Median NT-proBNP levels at baseline in subjects with newly detected AF after four years was 62.2 (22.6 to 208.5) pg/ml as compared with 35.7 (15.9 to 68.7) pg/ml in those with sinus rhythm (p=0.001). Each 1 standard deviation increment in natural log transformed NT-proBNP was associated with a 54% (5% to 126%, p=0.028) increase in risk for AF after adjustment for other risk factors predisposing to AF. NT-proBNP levels above the sex-specific 80th percentile (97 pg/ml in women and 60 pg/ml in men) were associated with a multivariate odds ratio of 2.65 (1.22 to 5.76, p=0.01) for the occurrence of AF. CONCLUSION: Plasma levels of NT-proBNP predict newly detected AF in subjects obtained from the general population independent of cardiovascular risk factors predisposing to AF. (Neth Heart J 2008;16:73-8.).
Authors: Tom D J Smilde; Folkert W Asselbergs; Hans L Hillege; Adriaan A Voors; Jan A Kors; Ron T Gansevoort; Wiek H van Gilst; Paul E de Jong; Dirk J Van Veldhuisen Journal: Am J Hypertens Date: 2005-03 Impact factor: 2.689
Authors: Aldo P Maggioni; Roberto Latini; Peter E Carson; Steven N Singh; Simona Barlera; Robert Glazer; Serge Masson; Elisabetta Cerè; Gianni Tognoni; Jay N Cohn Journal: Am Heart J Date: 2005-03 Impact factor: 4.749
Authors: Teresa S M Tsang; Bernard J Gersh; Christopher P Appleton; A Jamil Tajik; Marion E Barnes; Kent R Bailey; Jae K Oh; Cynthia Leibson; Samantha C Montgomery; James B Seward Journal: J Am Coll Cardiol Date: 2002-11-06 Impact factor: 24.094
Authors: T A McDonagh; S D Robb; D R Murdoch; J J Morton; I Ford; C E Morrison; H Tunstall-Pedoe; J J McMurray; H J Dargie Journal: Lancet Date: 1998-01-03 Impact factor: 79.321
Authors: B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju Journal: Circulation Date: 1997-10-07 Impact factor: 29.690
Authors: Patrick T Ellinor; Adrian F Low; Kristen K Patton; Marisa A Shea; Calum A Macrae Journal: J Am Coll Cardiol Date: 2005-01-04 Impact factor: 24.094
Authors: Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett Journal: J Am Coll Cardiol Date: 2002-09-04 Impact factor: 24.094
Authors: Priit Pauklin; Mihkel Zilmer; Jaan Eha; Kaspar Tootsi; Mart Kals; Priit Kampus Journal: Oxid Med Cell Longev Date: 2022-05-23 Impact factor: 7.310
Authors: F W Asselbergs; M P van den Berg; S J Bakker; J E Signorovitch; H L Hillege; W H van Gilst; D J van Veldhuisen Journal: Neth Heart J Date: 2008 Impact factor: 2.380
Authors: Renate B Schnabel; Martin G Larson; Jennifer F Yamamoto; Lisa M Sullivan; Michael J Pencina; James B Meigs; Geoffrey H Tofler; Jacob Selhub; Paul F Jacques; Philip A Wolf; Jared W Magnani; Patrick T Ellinor; Thomas J Wang; Daniel Levy; Ramachandran S Vasan; Emelia J Benjamin Journal: Circulation Date: 2010-01-04 Impact factor: 29.690
Authors: Ahmad Shoaib Amin; René H J Peters; Maaike Verstraaten; Arthur A M Wilde; Eugène M Buijs Journal: Neth Heart J Date: 2015-03 Impact factor: 2.380